Sanjay Shukla - 09 Jan 2026 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role: President and CEO, Director
Signature: /s/ Nancy E. Denyes, attorney-in-fact
Issuer symbol: ATYR
Transactions as of: 09 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Jan 2026, 17:46:19 UTC
Previous filing: 04 Feb 2025
Next filing: 04 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Shukla Sanjay	President and CEO, Director	10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO	/s/ Nancy E. Denyes, attorney-in-fact	09 Jan 2026	0001671026

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATYR	Employee Stock Option (right to buy)	Award	$0	+1,500,000		$0.000000	1,500,000	09 Jan 2026	Common Stock	1,500,000	$0.7127	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning February 9, 2026, such that this option will be fully exercisable on January 9, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.